Cabaletta Bio, Inc. Class Action Lawsuit

Company Name:              Cabaletta Bio, Inc.
Stock Symbol:                   CABA
Class Period:                     October 24, 2019 to December 13, 2021
Motion Deadline:             April 29, 2022
Court:                                 Eastern District of Pennsylvania

Investor who suffered losses in Cabaletta Bio Files Cabaletta Bio Class Action Lawsuit

If you suffered losses in Cabaleta Bio stock, call a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit

Investor Files Cabbalatta Bio Class Action Lawsuit

Call a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit

The Cabaletta Bio, Inc. class action lawsuit seeks to represent purchasers of Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to the offering documents issued in connection with Cabaletta Bio’s initial public offering conducted on or about October 24, 2019 (the “IPO”); and/or (b) securities between October 24, 2019 and December 13, 2021, inclusive (the “Class Period”).  Commenced on February 28, 2022, the Cabaletta Bio class action lawsuit – captioned Patterson v. Cabaletta Bio, Inc., No. 22-cv-00737 (E.D. Pa.) charges Cabaletta Bio as well as certain of its top executives and directors with violations of the Securities Act of 1933 and/or Securities Exchange Act of 1934. If you have questions, contact Cabaletta Bio Lawyer Timothy L. Miles about the Cabaletta Bio class action lawsuit.

If you suffered losses in Cabaletta Bio and wish to serve as lead plaintiff of the Cabaletta Bio class action lawsuit, please provide your information by submitting the form below.  You can also contact Cabaletta Bio Lawyer Timothy L. Miles  by calling 855/846-6529 or via e-mail at tmiles@tmileslaw.com.  Lead plaintiff motions for the Cabaletta Bio class action lawsuit must be filed with the court no later than April 29, 2022.   If you have questions, or need any additional information, contact Cabaletta Bio Lawyer Timothy L. Miles.

---

Allegations in Cabaletta Bio Class Action Lawsuit

Call Cabaletta Bio Lawyer Timothy L. Miles about your eligibility in the Cabaletta Bio class action lawsuit

Cabaletta Bio’s lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris (the “Phase 1 Clinical Trial”), an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.  Pursuant to its IPO, Cabaletta Bio sold approximately 6.8 million shares of common stock priced at $11.00 per share, for approximate proceeds of $69.5 million to Cabaletta Bio after applicable underwriting discounts and commissions, and before expenses.

The Cabaletta Bio class action lawsuit alleges that the IPO’s offering documents and defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as Cabaletta Bio had represented to investors; (iii) therefore, Cabaletta Bio had overstated DSG3-CAART’s clinical and/or commercial prospects; and (iv) as a result, Cabaletta Bio’s public statements were materially false and misleading at all relevant times.

On December 14, 2021, Cabaletta Bio issued a press release “report[ing] top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV).”  Among other results, Cabaletta Bio reported that two cohort participants had “disease activity scores . . . that worsened . . . after DSG3-CAART infusion” and thus “reduced or discontinued selected systemic therapies prior to DSG3-CAART infusion, as required by the protocol”, while another participant “subsequently received systemic medication to improve disease activity after DSG3-CAART infusion.”  On this news, Cabaletta Bio’s stock price fell by more than 73%, damaging investors.

As of the time the Cabaletta Bio class action lawsuit was filed, the price of Cabaletta Bio common stock continues to trade below the $11.00 per share IPO price.  If you suffered losses in Cabaletta Bio, contact ​Cabaletta Bio Lawyer Timothy L. Miles about the ​Cabaletta Bio, Inc. Class Action Lawsuit today.

---

The Lead Plaintiff Process

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Cabaletta Bio: (a) common stock pursuant and/or traceable to the offering documents issued in connection with the IPO, and/or (b) securities during the Class Period to seek appointment as lead plaintiff in the Cabaletta Bio class action lawsuit.  A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.  A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit.  The lead plaintiff can select a law firm of its choice to litigate the class action lawsuit.  An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in Cabaletta Bio, contact Cabaletta Bio Lawyer Timothy L. Miles for a free case evaluation about a Cabaletta Bio Class Action Lawsuit. 

How Can a Cabaletta Bio Lawyer Help Me?

​​A Cabaletta Bio Lawyer is well-versed in the complex laws that govern the securities industry and litigation.  A Cabaletta Bio Lawyer focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals.  Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, if they have lost money due to mistakes, incompetence, or fraud by an investment professional.  While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discovery every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct, such as a Cabaletta Bio Lawyer who will work to recover the losses you sustained.​

Call a Cabaletta Bio Lawyer About a Cabaletta Bio Class Action Lawsuit

​We have extensive experience in securities fraud class and other class actions.  If you suffered losses in Cabaletta Bio stock fill out our case evaluation form right away and see what a Cabaletta Bio Lawyer can do for you and if you have a case for a Cabaletta Bio Class Action Lawsuit because you suffered losses in Cabaletta Bio stock. 

If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit

​CONTACT US FOR A FREE CABALETTA BIO CLASS ACTION LAWSUIT CASE EVALUATION WITH CABALETTA BIO LAWYER TIMOTHY L. MILES  

Call Cabaletta Bio Lawyer Timothy L. Miles for a Free Case Evaluation

ATTENTION: CABALETTA BIO CLASS ACTION LAWSUIT
If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer​
​for free about a Cabaletta Bio class action lawsuit today. We are here to help.

Cabaletta Bio Lawyer
​855-Tim-MLaw (855) 846-8529
tmiles@timmileslaw.com
If you suffered losses in Cabaletta Bio, call a Cabaletta Bio Lawyer
​today for a free case evaluation about a Cabaletta Bio Class Action Lawsuit.

FREE CASE EVALUATION
Call today for a free, no-obligation case evaluation with a Cabaletta Bio Lawyer about a Cabaletta Bio Class Action Lawsuit.